Introduction {#Sec1}
============

Dietary intake of long-chain n-3 polyunsaturated fatty acids (PUFAs), like docosahexaenoic acid (DHA; 22:6 n-3) and eicosapentaenoic acid (EPA; 20:5 n-3), is known to have beneficial health effects in both humans and animals, which are partly explained by a reduction of inflammatory processes (Calder [@CR16], [@CR17]; Carpentier et al. [@CR19]; Schmitz and Ecker [@CR46]). The mechanisms behind this are not completely understood, but involve binding of n-3 PUFAs to GPR120 (Oh et al. [@CR39]), their conversion to resolvins (Serhan et al. [@CR49]), and the alteration of the eicosanoid balance (Calder [@CR17]). Increased dietary intake of n-3 PUFAs leads to enhanced incorporation of DHA and EPA in cell membranes, at the expense of incorporation of the n-6 PUFA arachidonic acid (ARA; 20:4 n-6). This results in decreased synthesis of ARA-derived eicosanoids, for example PGE~2~, after e.g. an inflammatory stimulus (Calder [@CR18]). At the same time, increased levels of n-3 fatty acid derived eicosanoids are observed. These n-3 fatty acid derived metabolites are often referred to as '3-series' or '5-series' oxylipins, comprising structures like prostaglandin D~3~ (PGD~3~), PGE~3~, thromboxane B~3~ (TBXB~3~), and 5-hydroxyeicosapentaenoic acid (5-HEPE), or leukotriene B~5~ (LTB~5~), respectively (see Fig. [1](#Fig1){ref-type="fig"} for an overview of oxylipins and their origin). These compounds are in general also pro-inflammatory, but considered less potent than the ARA-derived metabolites under certain circumstances, thereby contributing to a reduction of the general inflammatory status and specific inflammatory processes associated with fish oil (FO) consumption (Calder [@CR16], [@CR17]; Schmitz and Ecker [@CR46]).Fig. 1Overview of several enzymatic pathways involved in oxylipin synthesis, which are under investigation in the present paper. ARA, LA, EPA and DHA can serve as substrates, yielding distinct oxylipins and intermediates

Over the last decades, several endocannabinoids and related *N*-acyl ethanolamines (NAEs) have emerged as important regulators of metabolism and inflammation (De Petrocellis et al. [@CR21]; Di Marzo [@CR22]; Matias et al. [@CR35]; O'Sullivan [@CR40]). Like the oxylipins, these compounds are also derived from fatty acids following incorporation in cell membranes (Bisogno [@CR12]; Ueda et al. [@CR53]). Arachidonoyl ethanolamide (anandamide, AEA) and 2-arachidonoyl glycerol (2-AG) are two endocannabinoids which are derived from ARA, but combinations derived with other fatty acids also exist, such as palmitoyl ethanolamide (PEA) and the n-3 fatty acid derived NAEs docosahexaenoyl ethanolamide (DHEA), eicosapentaenoyl ethanolamide (EPEA). Both AEA and PEA are known for their anti-inflammatory properties (Cencioni et al. [@CR20]; Re et al. [@CR44]).

Several in vitro and animal studies have demonstrated a link between availability of specific fatty acids in the diet and the presence of endocannabinoids and related NAEs. Berger and coworkers reported enhanced levels of anandamide and 2-AG in piglet brain after feeding milk supplemented with ARA, with a diet rich in DHA showing even higher levels of its NAE metabolite, DHEA (Berger et al. [@CR11]). Wood and coworkers showed that a two-week diet rich in DHA elevated plasma and brain levels of DHEA in mice, while decreasing plasma 2-AG (Wood et al. [@CR56]). Artmann and coworkers demonstrated that feeding rats a FO diet, by nature rich in n-3 PUFAs, decreased jejunal levels of AEA and PEA, but increased the levels of n-3 NAEs DHEA and EPEA (Artmann et al. [@CR2]). Fish oil also decreased adipose tissue levels of AEA and 2-AG in a rat model of obesity (Batetta et al. [@CR8]). It thus seems that the profile of NAEs represents the relative abundance of fatty acids in the diet. Recently, is was shown that DHEA and EPEA display anti-inflammatory properties in macrophages and adipocytes (Balvers et al. [@CR4]; Meijerink et al. [@CR36]), indicating that these compounds might be involved in the anti-inflammatory effects which are related to dietary n-3 PUFA intake.

In addition to diet, inflammation is known to affect the synthesis and/or release of both oxylipins and NAEs (Maccarrone et al. [@CR34]), but it is not known how inflammation itself affects e.g. DHEA and EPEA tissue levels in vivo. Moreover, it is not known if changes induced by dietary fatty acids also persist under inflammatory conditions, or if the effect of diet is different under inflammatory conditions.

In the present study, we systematically explored in detail the (combined) effect of dietary FO and inflammation on levels of endocannabinoids/NAEs and oxylipins in plasma, liver, ileum and adipose tissue of wild type C57BL/6 mice using a targeted lipidomic approach. In total, levels on 61 compounds were analyzed, including levels of PGE~3~, PGD~3~, TBX-B~3~, 5-HEPE, resolvin D~1~, DHEA and EPEA. Both univariate and multivariate data analysis tools were used to assess differences in metabolite patterns between the intervention groups. Our data show in detail that dietary intake of FO shifted the n-3 to n-6 balance in the endocannabinoid and oxylipin metabolomes in all tissues examined. In addition, the direction of this shift appeared to be affected by inflammation, and was different between the examined tissues.

Materials and methods {#Sec2}
=====================

Chemicals and reagents {#Sec3}
----------------------

Lipopolysaccharide (0111: B4; LPS), indomethacin, paraoxon and butylated hydroxytoluene (BHT) were from Sigma (Steinheim, Germany). Phenylmethylsulfonyl fluoride (PMSF) was from Fluka (Steinheim, Germany). 12-\[(tricyclo\[3.3.1.13,7\]dec-1-ylamino)carbonyl\]amino\]-dodecanoic acid (AUDA) and URB602 was purchased from Cayman (Ann Arbor, MI, USA). Milli-Q water (Milli-Q Advantage unit, Millipore, Amsterdam, The Netherlands) was used in all analyses. ULC-grade acetonitrile (ACN), formic acid (FA) and trifluoro acetic acid (TFA) were obtained from Biosolve (Valkenswaard, The Netherlands). LC--MS grade methanol was from Riedel-de-Häen (Steinheim, Germany). Isopropanol and ethanol were from JT Baker (Deventer, The Netherlands). All analytical and internal standards, except EPEA, were purchased from Cayman. EPEA was synthesized as described earlier (Plastina et al. [@CR41]). For oxylipins, stock solutions were prepared in ethanol, aliquoted and stored at −80 °C until analysis. For endocannabinoids/NAEs, stocks were prepared in ACN, aliquoted and stored at −80 °C until analysis. C8 SPE columns (Bond Elut; 200 mg, 3 mL) were from Varian Inc. (Lake Forest, CA, USA). HLB SPE columns (Oasis, 60 mg, 3 mL) were from Waters (Etten-Leur, The Netherlands). ELISA kits were from R&D Systems (Minneapolis, MN, USA).

Animal experiment {#Sec4}
-----------------

Wild type male C57BL/6 mice were obtained from Harlan (Horst, The Netherlands) and housed two or three per cage in a temperature controlled environment with a 12 h light--dark cycle (light at 6.00--18.00). The mice, 4 weeks old at arrival, had free access to a standard run-in diet (AIN93-M, with a 4 % w/w fat content whereof 1 % soy bean oil and 3 % high-oleic acid sunflower oil (HOSF)) for 2 weeks. At the age of 6 weeks the mice were divided into three groups of 16 mice; group 1 was kept on the standard diet (control diet), group 2 received a diet containing AIN93-M with 1 % fish oil (1 % FO diet) (Marinol^®^), 2 % HOSF, and 1 % soy bean oil. The third group had access to a diet containing AIN93-M with 1 % soy bean oil and 3 % fish oil (3 % FO diet). The diets and water were available ad libitum. Diets were prepared by Research Diet Services (Wijk bij Duurstede, The Netherlands) and the Marinol^®^ was a kind gift from Lipid Nutrition (Wormerveer, The Netherlands). Diets were stored in air-tight bags at −20 °C until just before feeding, and fresh food was provided two times per week to minimize oxidation of the fatty acids in the diet. GC--MS based analysis of the diets confirmed that the correct amounts of DHA and EPA were present, and re-analysis after 4 weeks revealed that its amounts were stable under the described conditions (data not shown). Food consumption and animal weight were measured two times per week, revealing no differences between the diet groups.

The diets were continued for 6 weeks, after which the animals received either i.p. saline (eight mice per diet group) or 2 mg/kg LPS (eight mice per diet group). After 24 h, the animals were anesthetized, blood was collected from the orbital sinus and captured in 1.3 mL EDTA coated tubes (Sarstedt; Etten-Leur, The Netherlands) and put on ice until centrifugation (10′, 10,000 rpm at 4 °C). After centrifugation, plasma was aliquoted. For oxylipin analysis, 200 μL plasma was stored in 1 mL methanol containing paraoxon, BHT, AUDA, indomethacin, and PMSF to prevent oxylipin oxidation and breakdown. For endocannabinoid/NAE analysis, 100 μL plasma was stored in the presence of PMSF and URB602. Subsequently, the animals were sacrificed by cervical dislocation after which liver, ileum and adipose tissue were collected and immediately snap-frozen in liquid nitrogen. All plasma and tissue samples were stored at −80 °C until further analysis. Analysis of plasma IL-6 and MCP-1 levels confirmed that LPS had triggered an inflammatory response by showing strongly increased IL-6 and MCP-1 levels in LPS-treated mice (data not shown).

The study was conducted according to the Netherlands Law on Animal Experiments, and approved by the local Animal Experiments Committee of Wageningen University.

Extraction of endocannabinoids/NAEs from plasma {#Sec5}
-----------------------------------------------

Plasma (100 μL) was thawed and 400 μL extraction mixture containing 100 μM PMSF and internal standards (AEA-d8, 2-AG-d8 and OEA-d4) in ACN was added while the sample was gently vortexed. After subsequent centrifugation (5 min at 13,000 rpm and RT), the supernatant was transferred to a clean Eppendorf tube and evaporated to dryness in a vacuum concentrator (Scanvac; Lynge, Denmark). The dried extracts were reconstituted in 100 μL ACN containing 0.1 % TFA and used for LC--MS/MS analysis.

Extraction of endocannabinoids/NAEs from tissues {#Sec6}
------------------------------------------------

Endocannabinoid/NAE were extracted from freeze--dried liver and ileum using a method adapted from a previously published protocol for plasma (Balvers et al. [@CR5]). Approximately 50 mg freeze--dried liver or 10 mg freeze--dried ileum were extracted by adding 1 mL extraction mixture (ACN) and sonication. The samples were centrifuged (5 min at 14,000 rpm), the supernatant was transferred to a clean 15 mL tube, and this was repeated once. The pooled ACN fractions were diluted with MQ water containing 0.13 % TFA until the final ACN concentration was 20 % prior to SPE clean-up as described before (Balvers et al. [@CR5]). In short, columns were washed with 20 % v/v ACN in MQ water containing 0.1 % TFA, eluted with 80 % v/v ACN in MQ water containing 0.1 % TFA and evaporated to dryness using vacuum centrifugation. The dried extracts were reconstituted in 100 μL ACN containing 0.1 % TFA and used for LC--MS/MS analysis.

For adipose tissue, approximately 100 mg 'wet' tissue was extracted with 1 mL extraction solution (ACN) by sonication. The samples were centrifuged for 5 min at 14,000 rpm and RT, the supernatant was transferred to a clean 2.0 mL Eppendorf tube, and the ACN extraction was repeated once. The 2 mL ACN extract was subsequently evaporated to dryness, reconstituted in 100 μL ACN containing 0.1 % TFA and used for LC--MS/MS analysis.

LC--MS/MS analysis of endocannabinoids/NAEs {#Sec7}
-------------------------------------------

Two LC--MS/MS systems were used for endocannabinoid/NAE analysis. Plasma extracts were analyzed by UPLC coupled to a Xevo TQ-S mass spectrometer (Waters; Etten-Leur, The Netherlands) because high sensitivity was essential for adequate quantification in extracts obtained from 100 μL plasma samples. Liver, ileum and adipose tissue were analyzed on a Surveyor HPLC coupled to a TSQ Quantum Discovery mass spectrometer (Thermo Finnigan; Breda, The Netherlands).

For the UPLC-Xevo system, 3 μL plasma extract was injected on a Acquity C8 BEH UPLC column (2.1 × 100 mm, 1.7 μm) and was separated using gradient elution with a stable flow of 500 μL/min. The gradient started with 100 % A (40:40:20 v/v/v of MQ water:methanol:ACN with 0.1 % FA) which was maintained until 0.35 min, followed by a linear increase to 100 % B (7:3 v/v methanol:ACN with 0.1 % FA) which was achieved at 7.0 min and was maintained until 9.0 min. Finally, the column equilibrated for 3 min at 100 % A. The column was maintained at 60 °C during analysis, and the samples were kept at 10 °C. The MS was operating in selective reaction mode using electrospray ionization in positive ion mode, with a capillary voltage of 1.5 kV, a source temperature of 150 °C and a desolvation temperature of 500 °C. Cone voltage and collision energy were optimized for each compound individually (see supplemental data S-1 for parent and product *m/z* values). Peak identification and quantification was performed using MassLynx software version 4.1. Calibration curves were run in duplicate from which one regression equation was generated.

For the analysis of liver, ileum and adipose tissue, a TSQ Quantum Discovery was used as described before (Balvers et al. [@CR5]). Five microliters extract was separated on an Xterra C8 MS column (2.1 × 150 mm, 3.5 μm) using gradient elution with a constant flow of 150 μL/min. The same solutions were used as in the Xevo system, but now 1 g/L ammonium acetate was added (the most dominant parent for 2-AG in this MS is the ammonium adduct). The gradient started with 100 % A which was maintained until 2.0 min, followed by a linear increase to 100 % B which was achieved at 8.00 min and maintained until 16.0 min, and the column was left to equilibrate for 5 min at 100 % A. The column was maintained at 40 °C during analysis and the samples were cooled at 4 °C. The MS was operating in selective reaction mode using electrospray ionization in positive ion mode, with a capillary voltage of 4.5 kV and a capillary temperature of 350 °C. Cone voltage and collision energy were optimized for each compound individually. Peak identification and quantification was performed using LCquan software version 2.5.5. Calibration curves were run in duplicate from which one regression equation was generated. Quality control samples were included in each analytical run to check the quality of the analysis and to correct for accuracy.

Extraction of oxylipins from plasma {#Sec8}
-----------------------------------

Internal standards were added to the plasma samples which were already precipitated with methanol (see section '[2.2](#Sec4){ref-type="sec"}'), and the samples were put on ice for 30 min. Samples were subsequently centrifuged (5 min at 3,000×*g* and 4 °C) and the supernatant was transferred to a glass tube. Just before loading on activated HLB columns, 4.75 mL MQ water containing 0.1 % v/v FA was added to the methanol extract, diluting the extract to 20 % methanol. After loading, the columns were washed with 2 mL 20 % methanol in MQ water containing 0.1 % FA, and the columns were allowed to dry for 15 min. The SPE columns were eluted with 2 mL methanol and the samples were captured in tubes already containing 20 μL of 10 % glycerol and 500 μM BHT in ethanol. The tubes were placed in a water bath at 40 °C and the methanol was evaporated under a gentle stream of nitrogen, after which the samples were reconstituted in 100 μL ethanol containing another internal standard (CUDA) and immediately used for LC--MS/MS analysis.

Extraction of oxylipins from tissues {#Sec9}
------------------------------------

The extraction of oxylipins from liver, ileum and adipose tissue was similar to plasma oxylipin extraction. Approximately 100 mg liver and adipose tissue, and 50 mg ileum was extracted with 1 mL methanol containing internal standards and sonication. After centrifugation (5 min at 3,000×*g* and 4 °C), the supernatants were transferred to clean tubes and the methanol extraction was repeated once. Just before loading on HLB SPE columns, 8 mL MQ water containing 0.1 % FA was added to the methanol extracts. For the SPE procedure and further, (see section '[2.6](#Sec8){ref-type="sec"}') Extraction of oxylipins from plasma'.

LC--MS/MS analysis of oxylipins {#Sec10}
-------------------------------

All oxylipin analyses were performed on a UPLC coupled to a Xevo TQ-S mass spectrometer (Waters). Five microliters extract was injected on a Acquity C18 BEH UPLC column (2.1 × 100 mm, 1.7 μm) and was separated using gradient elution with a stable flow of 600 μL/min. The gradient started with 95 % A (MQ water with 0.1 % FA) and 5 % B (ACN with 0.1 % FA) followed by a linear increase to 70 % A and 30 % B which was achieved at 5.0 min. This was followed by a linear increase towards 50 % B which was achieved at 11.25 min and maintained until 13.25 min. The system was subsequently switched to 100 % B, which was achieved at 15.75 min and maintained until 16.75 min, after which the column was left to equilibrate at 5 % B for approximately 3 min. The column was maintained at 50 °C during analysis, and the samples were kept at 10 °C. The MS was operating in selective reaction mode using electrospray ionization in negative ion mode, with a capillary voltage of 3.3 kV, a source temperature of 150 °C and a desolvation temperature of 600 °C. Cone voltage and collision energy were optimized for each compound individually (see supplemental data S-1 for parent and product *m/z* values). Peak identification and quantification was performed using MassLynx software version 4.1. Calibration curves were run in duplicate from which one regression equation was generated. During data analysis, five peaks of unknown identity were found to be influenced by diet or LPS treatment, and these compounds are listed UK1--UK5. These peaks were visible in the transitions *m/*z 295.2 \> 195.2 and *m/z* 295.2 \> 171.1. ARA, DHA and EPA were also determined using this method. Quality control samples were included in each analytical run to check the quality of the analysis and to correct for accuracy.

Data analysis {#Sec11}
-------------

Univariate analysis was performed with SAS version 9.1 (2002--2003 by SAS Institute Inc., Cary, NC, USA). ANOVA assumptions were checked for each variable. If these assumptions were not met, rank transformation was applied for that particular variable. Partial tests were performed using Tukey--Kramer multiple comparison correction. Benjamini and Hochberg false discovery rate correction (*q* = 5 %) was applied to correct for false positives (Benjamini and Hochberg [@CR10]). In all statistical tests that were performed, the null hypothesis (no effect) was rejected at the 0.05 level of probability (α = 5 %).

The added value of multivariate data analysis in addition to univariate statistics is that correlations between variables are taken into account, and thus also allows to reveal combinations of variables which are associated with differences between treatment groups. Multivariate data analysis summarizes all the variables into one variable by means of a linear combination, now called the 'principal component' (PC), which adds higher weights to variables that account for the highest level of variance in the original data. Using principal component analysis (PCA), we screened for group separation, outliers, (undesired) patterns and this was further analyzed with principal component discriminant analysis (PCDA). PCDA includes the original group designation of the animals in the model and is therefore called a supervised classification technique. PCA and PCDA were performed in the Matlab environment (R2008b, 1984--2008, The Mathworks Inc., Natick, MA, USA) using the PLS toolbox for Matlab version 5.0.3 (r 6466, 1995--2008, Eigenvector Research Inc., Wenatchee, WA, USA). PCA and PCDA are described in more detail elsewhere (Hoogerbrugge et al. [@CR29]; Joliffe [@CR31]). For all multivariate models data were autoscaled to mean zero and variance 1 for each variable. For PCDA, stability of the model was evaluated by 10-fold cross-validation, revealing correct classification rates of typically 80--100 %. PCA and PCDA were performed on the combined data ('fused data'), containing data on both endocannabinoids/NAEs and oxylipins from plasma, liver ileum and adipose tissue combined in one data set.

Results {#Sec12}
=======

FO diet and inflammation alter the endocannabinoid/NAE balance {#Sec13}
--------------------------------------------------------------

To investigate the effect of dietary n-3 fatty acids and inflammation on endocannabinoid/NAE and oxylipin levels, wild-type male C57BL/6 mice received a diet containing either no, 1 or 3 % w/w FO followed by either saline or 2 mg/kg LPS i.p. injection. Endocannabinoid/NAE levels were determined in plasma, liver, ileum and adipose tissue.

Detailed (quantitative) effects of dietary administration of fish-oil and administering LPS after 6 weeks compared to their relevant control treatments are provided in the supplemental data (S2-7), including some representative chromatograms (S-8). Significant differences between diet groups and LPS treatment were obtained with the ANOVA test and are summarized in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} for endocannabinoids/NAEs and Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"} for oxylipins. A *diet effect* is here defined as an effect of the diet which (in magnitude and direction) was the same for saline and LPS-treated mice. The term *LPS effect* refers to situations in which LPS induced a change in a concentration of a compound, which was similar for all diet groups. An *interaction effect* indicates that only certain (combinations of) diets with saline or LPS resulted in significant differences, and therefore separate comparisons ('partial tests') should be interpreted rather than main effects. Table [1](#Tab1){ref-type="table"} shows diet effects on NAEs/endocannabinoids, and [2](#Tab2){ref-type="table"} LPS effects. Compounds with an interaction effect are highlighted with \* in the tables, with further details provided in the supplemental data (S-5).Table 1Effect of the fish oil diets on endocannabinoid/NAE levels in plasma, liver, ileum and adipose tissue (diet effect)PlasmaLiverIleumAdi. tiss.Ctrl vs 1 % FOn-3 derivedEPEA2.51\*24.15943.096DHEA1.9152.9082.1233.241OtherAEA\*0.3120.3740.3502-AG0.4030.2160.3040.465DGLEA0.282--0.6500.562OEA0.7100.777--\*Ctrl vs 3 % FOn-3 derivedEPEA3.688\*67.069116.975DHEA2.1664.6912.7745.484OtherAEA\*--0.8110.4232-AG0.3010.1560.2720.607DGLEA0.250--↓0.578OEA0.5220.663--\*SEA0.692----1.5741 % FO vs 3 % FOn-3 derivedEPEA--\*2.7762.714DHEA--1.6131.3061.692Other2-AG--0.724--1.304OEA0.735----\*SEA0.700----1.284Only statistically significant effects are listed, presented as fold-control values, calculated by comparing mean metabolite concentration from one diet to another. Means were calculated from saline and LPS treated animals together per diet group. ↑ or ↓ were used when the fold-control value would disagree with the outcome outcome of the ANOVA in cases of variables which were rank-transformed*ND* the compound was not detected in the particular matrix, and *--* indicates that no statistical significant differences were observed\*^ ^Interaction effect (see supplemental data for details)Table 2Effect of LPS on endocannabinoid/NAE levels in plasma, liver, ileum and adipose tissue (LPS effect)PlasmaLiverIleumAdi. tiss.Saline vs LPSn-3 derivedEPEA2.019\*--1.766DHEA2.1014.1301.3381.584OtherAEA\*3.3751.274--2-AG0.651----1.366DGLEA1.9611.611↑--PEA\*0.7431.406\*OEA3.0972.2761.260\*SEA2.0730.5401.6760.711Only statistically significant effects are listed, presented as fold-control values, calculated by comparing mean metabolite concentration from the saline to the LPS treated groups. Means were calculated from the different diet groups together for the saline and LPS treated animals. ↑ or ↓ were used when the fold-control value would disagree with the outcome outcome of the ANOVA in cases of variables which were rank-transformed*ND* the compound was not detected in the particular matrix, and *--* no statistical significant differences were observed\* Interaction effect (see supplemental data for details)Table 3Effect of the fish oil diets on oxylipin levels in plasma, liver, ileum and adipose tissue (diet effect)PlasmaLiverIleumAdi. tiss.Ctrl vs 1% FO Fatty acids  ARA\*0.326--0.520  DHA1.931--2.128--  EPA\*13.9324.18229.425 n-3 derived oxylipins  5-HEPE4.3587.4749.45934.105  12-HEPE\*4.75319.37924.735  PGD~3~NDND18.8283.937  PGE~3~--ND15.53412.614  17-HDoHE----3.0142.694  10-17-DiHDoHENDND2.5663.352  19,20-DiHoPE3.0401.5342.3814.447  TBXB~3~\*ND20.6574.809 n-6 oxylipins  5,6 EET--0.163----  11,12 EET--0.2930.4950.484  14,15 EET0.4920.3190.4760.497  LTB~4~ND3.3560.470\*  LTD~4~NDND0.184--  5,6-DiHETrE--0.2150.3920.383  8,9-DiHETrE0.3140.2130.378\*  11,12-DiHETrE0.2800.2490.4190.378  14,15-DiHETrE0.3270.2510.404\*  PGE~2~--0.205----  PGF~2α~--0.234----  8-iso-PGF~2α~------0.629  13,14-dihydro-15-keto-PGD~2~NDND0.292ND  13,14-dihydro-15-keto-PGE~2~↓0.3730.2420.198  13,14-dihydro-15-keto-PGF~2α~ND0.4320.2550.473  12-HHTrE--0.107--0.298  5-HETE0.4160.410--0.632  11-HETE--0.233--0.417  12-HETE--0.150----  15-HETE--0.211--0.252  20-HETEND0.419--ND  TBXB~2~--0.209----  13-HODE--0.570----  9,10,13-TriHOME--\*--0.686Ctrl vs 3% FO Fatty acids  ARA   \*0.302----  DHA   1.642--2.828--  EPA\*19.59737.80654.972  17 keto- 4(z), 7(z), 10(z), 13 (z), 15 (E), 19(z)-DHAND--2.830\* n-3 derived oxylipins  5-HEPE  7.430  12.323  19.378  163.982  12-HEPE  \*  7.684  33.107 55.445  PGD~3~ ND  ND  14.818 9.352  PGE~3~  --  ND23.562 32.107  17-HDoHE  --  2.051  3.362 3.148  10-17-DiHDoHE  ND  ND  3.384 4.768  19,20-DiHoPE 5.717  2.244  4.172  18.053  TBXB~3~  \*  ND 16.198 10.438 Other oxylipins  5,6 EET--0.120----  8,9 EETNDND0.329--  11,12 EET0.5120.1790.4890.566  14,15 EET0.4920.2770.537--  LTB~4~ND3.5240.357\*  LTD~4~NDND0.184--  n-acetyl-leukotriene E~4~ND0.628\*ND  5,6-DiHETrE0.358--0.2460.496  8,9-DiHETrE0.4810.1860.328\*  11,12-DiHETrE0.3030.2210.3880.593  14,15-DiHETrE0.5620.2240.366\*  PGD~2~0.363\*----  PGE~2~0.3970.229----  PGF~2α~--0.259----  8-iso-PGF~2α~------0.623  13,14-dihydro-15-keto-PGD~2~NDND0.180ND  13,14-dihydro-15-keto-PGE~2~0.4790.2750.1570.244  13,14-dihydro-15-keto-PGF~2α~ND0.2400.2000.405  12-HHTrE0.4210.094--0.224  5-HETE0.375------  11-HETE0.4010.094----  12-HETE0.2650.159--0.289  15-HETE0.3230.250--0.234  20-HETEND0.447--ND  TBXB~2~0.4030.215----  9-HODE------0.417  13-HODE0.559↓--0.308  lipoxin A~4~ND1.7712.5337.1811% FO vs 3% FO Fatty acids  DHA----1.329--  EPA\*--1.5631.868  17 keto- 4(z), 7(z), 10(z), 13 (z), 15 (E), 19(z)-DHAND--1.786\* n-3 derived oxylipins  5-HEPE--1.6492.0494.808  12-HEPE\*--1.7082.242  PGD~3~NDND--2.545  PGE~3~--ND--2.375  17-HDoHE--1.435----  19,20-DiHoPE--1.463-4.060 Other oxylipins  5-HETE----0.4161.739  11-HETE0.487------  13-HODE0.651------  15-HETE0.442------  PGE~2~0.492------  13,14-dihydro-15-keto-PGE~2~----0.648--  13,14-dihydro-15-keto-PGF~2α~ND0.555----  lipoxin A~4~ND2.0752.8776.588  TBXB~2~0.433------Only statistically significant effects are listed, presented as fold-control values, calculated by comparing mean metabolite concentration from one diet to another. Means were calculated from saline and LPS treated animals together per diet group. ↑ or ↓ were used when the fold-control value would disagree with the outcome outcome of the ANOVA in cases of variables which were rank-transformed*ND* the compound was not detected in the particular matrix, and '*--*' indicates that no statistical significant differences were observed\* Interaction effect (see supplemental data for details)Table 4Effect of LPS on oxylipin levels in plasma, liver, ileum and adipose tissue (LPS effect)PlasmaLiverIleumAdi. tiss.Saline vs LPSFatty acidsARA\*1.827--1.854DHA2.0331.590----EPA\*----1.791n-3 derived oxylipins5-HEPE2.049----5.626PGD~3~NDND--2.498PGE~3~--ND3.2564.21710(S)-17(S)-DiHDoHENDND--2.24919,20-DiHoPE3.8861.3761.8743.822TBXB~3~\*ND2.6374.752Other oxylipins5,6 EET------2.84711,12 EET------1.84314,15 EET--1.890----LTB~4~ND0.538--\*LTD~4~NDND--2.445n-acetyl leukotriene E~4~ND1.627\*ND5,6 DiHETrE------1.7448,9-DiHETrE2.170----\*11,12-DiHETrE2.167------14,15-DiHETrE1.943----\*PGE~2~1.9582.449--2.039PGF~2α~------1.7778-iso-PGF~2α~--1.778----13,14-dihydro-15-keto-PGE~2~2.600----1.24313,14-dihydro-15-keto-PGF~2α~ND1.815----12-HHTrE0.201----2.2525-HETE2.240----2.43511-HETE0.5611.887--1.92512-HETE--0.782----15-HETE0.433------20-HETEND2.399--NDTBXB~2~0.175--2.5602.2779-HODE1.267--2.7682.01413-HODE----2.0861.2069,10,13-TriHOME1.301\*----Lipoxin A~4~ND----2.372Only statistically significant effects are listed, presented as fold-control values, calculated by comparing mean metabolite concentration from the saline to the LPS groups. Means were calculated from the different diet groups together for saline and LPS treated animals.*ND* the compound was not detected in the particular matrix, and *--* indicates that no statistical significant differences were observed\* Interaction effect (see supplemental data for details)

The FO diets altered endocannabinoid levels with different effects in plasma, liver, ileum and adipose tissue (Table [1](#Tab1){ref-type="table"}). DHEA was increased by both FO diets in all compartments compared to control diet. For EPEA, an interaction effect (see supplemental data) was observed in liver, but the compound was increased by the FO diets in plasma, ileum and adipose tissue. The endocannabinoids/NAEs derived from other fatty acids, such as AEA and 2-AG, were in general decreased by the FO diets, but some deviations were observed. For instance, 2-AG levels in adipose tissue and liver were decreased in both FO groups compared to the control diet. When comparing the 1 % versus the 3 % FO group, liver 2-AG was lower in the 3 % group, but higher in adipose tissue. DGLEA (also known as DLE) in liver was not influenced by the diets, but was decreased in plasma, ileum and adipose tissue in the FO groups. OEA was decreased in liver and plasma, but not in ileum. When comparing the control diet group with the 3 % FO group, SEA displayed opposite effects in adipose tissue and plasma; FO was found to decrease plasma levels, but increased adipose tissue levels of SEA. This was also observed when comparing the 1 % versus the 3 % FO groups.

The effect of LPS on endocannabinoids appeared to be both compound and tissue specific (Table [2](#Tab2){ref-type="table"}; for effects of LPS on endocannabinoids for each diet group, please refer to the supplemental data). LPS increased DHEA levels in all compartments, but for some compounds tissue-specific effects were seen. LPS decreased plasma 2-AG, whereas it increased adipose tissue 2-AG. A similar divergence is seen for SEA and PEA. LPS increased plasma and ileum SEA levels, but decreases liver and adipose tissue SEA levels. PEA levels were decreased in liver by LPS, but increased in ileum.

In summary, both the FO diets and the LPS treatment affected plasma and tissue endocannabinoid/NAE levels. In general, DHEA and EPEA were increased by the FO diets, and compounds derived from other fatty acids were decreased, with different effects for 1 and 3 % FO diets. LPS raised endocannabinoid/NAE levels in general, but opposing effects were seen for 2-AG, PEA and SEA across the tissues investigated.

FO diet and inflammation alter the oxylipin balance {#Sec14}
---------------------------------------------------

The results of the oxylipin analyses in plasma, liver, ileum and adipose tissue are presented in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}, with Table [3](#Tab3){ref-type="table"} showing diet effects and Table [4](#Tab4){ref-type="table"} LPS effects. Compounds with an interaction effects are highlighted with an \* in the tables, with details provided in the supplemental data (S-5 and S-6). UK compounds are not presented in Table [5](#Tab5){ref-type="table"}, but can be found in the supplemental data.Table 5Top lists generated from PCA analysisPC1PC2P_AEA0.13562F_pea0.148486P_AA0.128696L_dhea0.141097P_DLE0.12706F_TBXB30.138751L_13,14-dihydro-15-keto-PGF2a0.120315P_DHEA0.137637L_AA0.12015P_19,20-DiHoPE0.137193L_2-ag0.116734F_UK30.136532P_11,12-DiHETrE0.116219F_5(S)-HETE0.136382L_8,9-DiHETrE0.115152F_17 keto- 4(z), 7(z), 10(z), 13 (z), 15 (E), 19(z)-DHA0.135592I_13,14-dihydro-15-keto-PGE20.114106F_PGE30.133149I_2-ag0.113331F_19,20-DiHoPE0.133074L_15(S)-HETE0.112971F_oea0.132124F_aea0.112488F_UK50.131976L_EPA−0.11245F_UK20.128994L_14,15 EET0.111192I_PGE30.128277~L_5(S)-HEPE~−0.11066F_UK40.127957L_11(S)-HETE0.10907P_DHA0.127188P_14,15-DiHETrE0.107335F_AA0.125684I_13,14-dihydro-15-keto-PGF2a0.105203F_5(S)-HEPE0.12297P_8,9-DiHETrE0.104781I_19,20-DiHoPE0.121367L_11,12 EET0.103724F_12,13-DiHOME0.12071I_13,14-dihydro-15-keto-PGD20.100174P_PEA0.120517L_PGE20.100147P_12,13-DiHOME0.118135I_12(S)-HEPE−0.09961F_lipoxin A40.115389F_2-ag0.099293P_EPEA0.115294L_14,15-DiHETrE0.098683F_5,6 EET0.115132L_12(S)-HHTrE0.098509F_PGD30.114641I_EPA−0.09806F_dhea0.113431F_dle0.09791L_epea0.112967F_13,14-dihydro-15-keto-PGF2a0.097779P_9,10-DiHOME0.11289F_EPA−0.09662F_9,10-DiHOME0.109149The D-scores represent the variable's weight in the separation, and is expressed as the numerical output value as obtained from the PCA model; the further away from zero, the better this variable accounts for group separation. PC1 separated the diets, whereas PC2 separated between saline and LPS treatment*P* plasma, *L* liver, *I* ileum, *F* adipose tissue

The FO diets decreased levels of ARA and increased DHA and EPA, confirming that the increased dietary intake of n-3 fatty acids was reflected in tissue fatty acid levels (Table [3](#Tab3){ref-type="table"}). Furthermore, n-3 derived oxylipin levels were increased by the FO diets, with the most pronounced effects observed in ileum and adipose tissue. The oxylipins derived from other fatty acids were in general decreased by the FO diets, with some exceptions, and effects were not always consistent over all tissues tested. Levels of LTB~4~ were decreased in ileum and adipose tissue by the FO diets, but liver levels were increased. Lipoxin A~4~ levels were increased in the 3 % FO group compared to the control and 1 % FO diet in liver, ileum and adipose tissue. When comparing the 1 and 3 % FO diets, ileal 5-HETE levels were decreased in the 3 % FO group, but its level was increased in adipose tissue. The FO diets decreased oxylipins belonging to different branches of the fatty acid oxylipin cascade, including the cyclooxygenase pathway (COX; PGD~2~, PGE2 and their metabolites 13,14-dihydro-15-keto-PGD~2~ and --PGE~2~, PGF~2α~, TBXB~2~), the 15-lipo-oxygenase pathway (15-LOX; 15-HETE), 12-LOX (11-HETE and 12-HETE), 5-LOX (5-HETE, LTB~4~ and LTD~4~) and the cytochrome P450 pathways (EETs and DiHETrEs) (see Fig. [1](#Fig1){ref-type="fig"} for an overview).

Treatment with LPS generally resulted in increased levels of fatty acids, n-3 derived oxylipins and other oxylipins, with the most compounds affected in plasma and adipose tissue, and the least number of compounds altered in ileum (Table [4](#Tab4){ref-type="table"}; for effects of LPS on oxylipins for each diet group, please refer to the supplemental data). Again, opposing effects were observed between compartments for some components. LPS decreased plasma levels of 11-HETE, but increased liver levels. TBXB~2~ was decreased by LPS in plasma, but increased in ileum and adipose tissue. Effects on UK compounds are listed in the supplemental data.

Multivariate data analysis shows separation between diet groups and LPS treatment {#Sec15}
---------------------------------------------------------------------------------

The univariate data analysis approach revealed that both FO and LPS altered endocannabinoid/NAE and oxylipin levels, and effects were seen in plasma, liver, ileum and adipose tissue. In total, 244 variables obtained in four compartments were evaluated, which were, due to complexity, further analyzed with multivariate data analysis to evaluate differences between treatment groups. Two methods were used, the unbiased PCA and the supervised PCDA. In the PCA plot (Fig. [2](#Fig2){ref-type="fig"}), a good separation of the six intervention groups can be seen. PC1 separated the diets, with negative loadings associated to n-3 fatty acid derived metabolites, and positive loadings belonging to other metabolites. From the top-30 variables relevant for group separation in PC1 (see Table [5](#Tab5){ref-type="table"}), 13 variables were from liver, whereas plasma, ileum and adipose tissue were equally important. In total four metabolites were derived from n-3 fatty acids, and 26 were derived from other fatty acids. PC2 separated between saline and LPS treatment, containing equal numbers of n-3 derived- and other metabolites. From the top-30 variables accounting in PC2, 19 metabolites were from adipose tissue, with 15 n-3 fatty acid derived metabolites, and 15 derived from other fatty acids.Fig. 2PCA analysis on fused data. The PCA plot shows good separation of the three diet groups. PC1 describes mainly the diet effect, and PC2 mainly the LPS effect

The diet effect in the saline treated mice is explained by other variables than the diet effect in the LPS-treated mice {#Sec16}
-----------------------------------------------------------------------------------------------------------------------

To further explore differences between diet groups, PCDA was performed. The data was split for saline and LPS-treated mice, thus resulting in two separate PCDA plots. PCDA analyses showed that there is separation based on diet for both the saline and LPS-treated mice (Fig. [3](#Fig3){ref-type="fig"}). The contribution of a variable in the PCDA model is expressed as its D-score, with a positive score meaning an increase by the FO diets, and a negative score indicating a decrease. Analysis of D-scores focused on the 50 compounds with the highest D-scores as there was considerable decay in D-score values between the first and 50th compound, meaning that any differences within this range can be considered as a potentially meaningful difference. The analysis revealed that the diet groups are separated by increased levels of n-3 derived compounds in the FO groups, and compounds derived from other fatty acids were generally decreased by the FO diets (Table [6](#Tab6){ref-type="table"}). In addition to this, both endocannabinoids/NAEs and oxylipins show up in the top of the rank lists, indicating that both classes of compounds are important to describe the diet effect. The ranking, number and origin of n-3 derived metabolites in the models is different between the saline and LPS treated animals. Out of the 50 compounds ranking highest for the saline treated mice, only 12 compounds are n-3 fatty acid derived metabolites, while for the LPS treated mice, the top-50 list contains 25 n-3 fatty acid derived metabolites. In addition to this, the majority of n-3 derived compounds in the LPS treated mice from this list originated from adipose tissue.Fig. 3PCDA analysis, split for saline and LPS treated mice. A separation of diet groups is observed in both saline and LPS treated mice, with a more prominent separation in the LPS treated miceTable 6Top lists for saline and LPS treated mice. Lists were generated from PCDA analysis, showing different patterns for saline and LPS treated miceSalineD-scoreLPSD-scoreP_AEA−4,6879L_2-AG−4,3994L_2-AG−4,5742P_AEA−4,2737P_DGLEA−4,54121**F_EPA4,2374**F_AEA−4,49142**F_12-HEPE4,1634**P_ARA−4,44863**P_EPA4,1441**P_11,12-DiHETrE−4,4257P_2-AG−4,10531**F_DHEA4,3978**P_AA−4,0854P_14,15-DiHETrE−4,39614**I_PGE**~**3**~**4,0450**L_ARA−4,39155**F_TBXB**~**3**~**4,0374**L_13,14-dihydro-15-keto-PGF~2a~−4,30256**F_PGE**~**3**~**3,9827**L_12-HETE−4,2590P_DGLEA−3,9498F_8,9-DiHETrE−4,2553L_14,15-DiHETrE−3,8977L_15-HETE−4,23437**F_DHEA3,89462L_5-HEPE4,21628I_EPA3,8541**L_11-HETE−4,15489**L_EPEA3,7505**3**L_EPA4,1323**L_11,12-DiHETrE−3,74104**P_EPA4,1269**10**L_DHEA3,7222**F_DGLEA−4,1166L_ARA−3,6999P_8,9-DiHETrE−4,089211**L_EPA3,6953**I_13,14-dihydro-15-keto-PGE~2~−4,078312**I_DHA3,6912**P_OEA−4,059213**I_12-HEPE3,6874**F_11,12 EET−4,0186L_8,9-DiHETrE−3,6672F_OEA−4,014814**F_EPEA3,6327**L_8,9-DiHETrE−4,0079L_13,14-dihydro-15-keto-PGF~2a~−3,6261I_2-AG−3,9897I_2-AG−3,6231F_9,10-DiHOME−3,914715**P_DHA3,5903**P_9,10-DiHOME−3,8645F_AEA−3,5678L_LTB43,8175L_PGD~2~−3,5455F_11,12-DiHETrE−3,760016**F_PGD**~**3**~**3,5197**F_14,15-DiHETrE−3,737617**F_19,20-DiHoPE3,5168**L_5,6 EET−3,7094L_AEA−3,5158I_13,14-dihydro-15-keto-PGF~2a~−3,700818**I_19,20-DiHoPE3,4924**P_12,13-DiHOME−3,6962L_14,15 EET−3,4871F_12,13-DiHOME−3,671819**I_EPEA3,4515**5**P_DHEA3,6677**20**I_5-HEPE3,4391**P_UK4−3,6605I_AEA−3,4310L_14,15 EET−3,6511F_SEA3,41876**F_EPA3,6069**L_20-HETE−3,41047**I_19,20-DiHoPE3,5938**I_13,14-dihydro-15-keto-PGE~2~−3,3956F_5,6-DiHETrE−3,535721**P_5-HEPE3,3787**P_2-AG−3,515522**L_5-HEPE3,3617**8**I_12-HEPE3,4899**L_TBXB~2~−3,3200L_11,12 EET−3,4781L_12-HHTrE−3,31559F_EPEA**3,4723**P_5,6-DiHETrE−3,308010L_19,20-DiHoPE**3,4679**23**F_5-HEPE3,3048**L_12-HHTrE−3,452524**P_DHEA3,2978**P_UK2−3,4144P_11,12-DiHETrE−3,2966L_PGE~2~−3,414325**F_17 keto- 4(z), 7(z), 10(z), 13 (z), 15 (E), 19(z)-DHA3,2931**11**I_EPA3,3758**L_11-HETE−3,279212**P_5-HEPE3,3581**P_15-HETE−3,2618The D-scores represent their weight, expressed as the numerical output value as obtained from the PCDA model; the further away from zero, the better this variable accounts for group separation. Negative scores indicate that the compound is decreased in the fish oil groups; positive scores mean that it is increased by fish oil. Decrease of other than n-3 derived compounds ranks relatively high in the saline diet effect, whereas an increase in n-3 derived compounds (printed in bold) ranks high for the diet effect in the LPS treated mice*P* plasma, *L*  liver, *I* ileum, *F* adipose tissue

From these results, it can be concluded that the diet effect of FO in the saline treated animals is mainly explained by a decrease of compounds derived from other than n-3 fatty acids, and to a lesser extent by an increase of n-3 derived metabolites. However, for the LPS treated mice, the diet effect is principally explained by an increase of n-3 derived metabolites, and to a lesser extent by a decrease of metabolites derived from other than n-3 fatty acids.

Discussion {#Sec17}
==========

Our results support the general idea that increasing dietary n-3 fatty intake results in increased levels of n-3 derived-endocannabinoids/NAEs and oxylipins. However, to the best of our knowledge, our study is the first one describing effects of dietary FO on the balance between the "endocannabinoid" and oxylipin pathways in such detail, in different compartments simultaneously, and in relation with inflammation. In addition, our study illustrates the risk of obtained potentially premature conclusions when only a few mediators are analyzed in a limited number of matrices. Several studies, focusing on for example AEA (anandamide) and 2-AG only, have concluded that dietary FO leads to an overall down regulation of the endocannabinoid system (Banni et al. [@CR6]; Batetta et al. [@CR8]). However, as we show other (n-3 derived-) endocannabinoids might be affected in an opposite direction following FO intake, and our data shows that the sum of all NAE levels in liver, ileum and plasma are actually quite stable with the different diets (data not shown). Although there are still several questions regarding their biological role, there are reports showing that n-3 derived ethanolamides have affinity for CB1 and CB2 receptors (Brown et al. [@CR14]; Plastina et al. [@CR42]), and have anti-inflammatory properties (Balvers et al. [@CR4]; Meijerink et al. [@CR36]).

LPS was found to produce a general increase of in vivo endocannabinoid/NAE and oxylipin levels, although there were some exceptions (see below). Multivariate data analysis showed that the diet effect was also present during inflammatory conditions. Without LPS, the effect of a FO diet was mainly explained by a reduction of mediators other than those derived from n-3 fatty acids, and to a lesser degree by increased levels of n-3 derived metabolites. However, after LPS, the balance was shifted in favor of an increase of n-3 derived mediators while lower associations were found with reductions of non n-3 derived metabolites.

The relation between dietary fatty acid intake and the presence of endocannabinoids/NAEs and oxylipins in plasma and tissues has been established before (Banni and Di Marzo [@CR7]; Hansen and Artmann [@CR26]), but not under conditions of inflammation. Previous work with rats demonstrated that patterns of organ levels of NAEs follow the relative abundance of fatty acids in the diet (Artmann et al. [@CR2]). Other work, investigating the effect of DHA on murine levels of endocannabinoids/NAEs in brain and plasma, showed strongest changes in plasma (Wood et al. [@CR56]). Interestingly, plasma AEA levels were not significantly affected by DHA alone, whereas other NAEs were decreased by DHA. Other work, supplementing krill oil or menhaden oil to human subjects also did not show an effect on plasma AEA levels (Banni et al. [@CR6]). Our work shows that 6 weeks of a FO diet is capable of reducing plasma AEA and 2-AG levels. This discrepancy might originate from differences in n-3 fatty acids sources, daily dose, or length of the period in which the n-3 fatty acids were supplemented.

Many studies analyze plasma levels of endocannabinoids/NAEs or oxylipins. The present work shows that plasma levels do not always reflect effects in liver, ileum or adipose tissue. For example, plasma 2-AG levels decreased after LPS, but were increased in adipose tissue, and similar divergences were also observed for PEA, SEA, several HETEs, and TBXB~2~. The origin and significance of these findings are not known yet, but this could be related to synthesis, release, uptake or breakdown which might be differentially regulated by LPS or other factors across different organs. Nevertheless, based on our results, extrapolating effects found in plasma to effects on peripheral tissues is not always appropriate. It should be noted that the recovery of endogenous metabolites from tissues might not be complete, potentially underestimating actual effects of the diet and inflammation in the tissues.

The LPS treated mice had a lower food intake combined with a small loss of body weight (data not shown), whereas the saline treated animals displayed normal food consumption and stable body weight. Previous work showed that levels of endocannabinoids and related NAEs depend on fasting status (Hansen and Diep [@CR27]; Joosten et al. [@CR32]; Li et al. [@CR33]); their tissue levels being high during fasting, followed by a rapid postprandial decrease. Possibly, the effect of LPS on endocannabinoid levels might in part be mediated through such a 'fasting' effect. In addition, inflammation reduces FAAH expression, and inhibition of FAAH or monoacyl glycerol lipase (MGL) has been shown to reduce disease symptoms in several models of inflammation (Alhouayek et al. [@CR1]; Maccarrone et al. [@CR34]; Naidu et al. [@CR38]). Similarly, studies using CB2 knock-out models under induced inflammatory conditions showed that increased levels of NAEs likely contribute to suppress inflammation (Bátkai et al. [@CR9]). Together, this suggests that increased levels of endocannabinoids/NAEs are part of a normal response protecting against inflammatory stress. Previous work identified DHEA and EPEA as having anti-inflammatory properties in macrophages and adipocytes (Balvers et al. [@CR4]; Meijerink et al. [@CR36]), and these compounds could be another link between FO and its anti-inflammatory effects as n-3 derived NAEs were more effective than AEA in suppressing nitric oxide release from macrophages (Meijerink et al. [@CR36]).

The FO diets also influenced levels of oxylipins, including metabolites from the COX, CYP450, and 5-LOX, 12-LOX and 15-LOX pathways (Fig. [1](#Fig1){ref-type="fig"}), and these effects were in general also seen during inflammatory conditions. Another strength of the present study is that we analyzed both n-6 and n-3 related oxylipins simultaneously in different compartments. In general, levels of n-3 fatty acid derived oxylipins (e.g. PGD~3~, PGE~3~, 5-HEPE, 12-HEPE and TBXB~3~) were increased with FO at the expense of oxylipins derived from other fatty acids (e.g. PGD~2~, PGE~2~, PGF~2α~, TBXB~2~ and members of the EET and HETE subclasses). A functional role in inflammation has been described for several of these compounds, and it is likely that the changes in profiles which are found in this study (and before) are causally related to the anti-inflammatory effects which are associated with n-3 fatty acid intake. For example, PGE~3~ is less potent than PGE~2~ in inducing COX-2 expression and IL-6 release (Bagga et al. [@CR3]). A similar principle applies to the thromboxanes (Fischer and Weber [@CR24]; von Schacky et al. [@CR55]) and for 5-HETE/5-HEPE (Heidel et al. [@CR28]), which were also altered by the FO diets.

Interestingly, the FO diets increased liver LTB~4~ levels, whereas ileum LTB~4~ levels were decreased. LTB~4~ has multiple pro-inflammatory functions in the immune system (Calder [@CR15]), but the different effect of FO on organ levels of LTB~4~ is not understood. Lipoxin A~4~, a compound with anti-inflammatory properties (Schwab and Serhan [@CR47]), was increased by the 3 % FO diet. This indicates that at least for this compound, which is synthesized from ARA, its levels are not directly related to dietary supply of precursors, but that other presently unknown factors are involved.

Levels of several EETs were reduced by the FO diets, especially in the liver. EETs play regulatory roles in heart and vascular physiology with effects on blood pressure regulation, but also have anti-inflammatory effects (Spector [@CR52]). It thus seems that EETs do not play a role in the anti-inflammatory properties of n-3 fatty acids, but it should be noted that n-3 fatty acid derived EET analogues are reported to be endogenously present and have potent analgesic properties (Morisseau et al. [@CR37]), but these specific EETs were not quantified in the current study. Another line of evidence suggests that EETs very specifically alter the release of either insulin or glucagon (Falck et al. [@CR23]; Sacerdoti et al. [@CR45]), pointing to a potential link between n-3 fatty acids and glucose metabolism. EETs might therefore also be part in mediating effects of dietary fatty acids on metabolism, but this relation has not been given much attention yet.

In the present study we did not detect resolvins in any of the samples. It might be that these compounds are not formed in quantities high enough to be detected with our method during the first 24 h after the initiation of the inflammatory response, or the detection limit of the analytical method was not sufficient to detect these compounds. The single time-point approach in the present study is a limitation of the work, and investigating a broader time range, e.g. studying multiple time points beyond 24 h after the initiation of inflammation, might reveal temporal changes in lipid mediators including resolvins.

The presence of 17-HDoHE (also known as 17-HDHA), a marker for resolvin synthesis (Poulsen et al. [@CR43]) with anti-inflammatory properties (González-Périz et al. [@CR25]), was increased by the FO diets. The FO diets as well as LPS increased levels of 10,17-DiHDoHE, (also known as protectin DX) which was previously shown to reduce inflammation and accelerate its resolution (Serhan et al. [@CR50]). Altogether, the FO diets altered all branches in the oxylipin metabolome in a way that is largely associated with suppression of inflammation.

A major finding of this work is that the effects of FO were also persistent under inflammatory conditions. Multivariate data analysis revealed that both endocannabinoids and oxylipins are responsible for separation between diet groups. Under non-inflammatory conditions, the diet groups could be primarily separated based on the reduction of other than n-3 derived endocannabinoids and oxylipins. In contrast, with LPS treatment, the diet groups were primarily separated by increases in levels of n-3 fatty acid derived endocannabinoids and oxylipins. The combined approach of comparing normal versus inflammatory conditions was thus useful in demonstrating that effects of diet on oxylipins and endocannabinoids are depending on inflammatory status.

Recent evidence suggested that relatively high intakes of FO impairs the host's resistance to microbial infection (Bonilla et al. [@CR13]; Irons et al. [@CR30]; Snel et al. [@CR51]). In our study, the mice that had received 3 % FO showed relatively more severe signs of shock after LPS, and one mouse from the 3 % FO + LPS group died shortly before the end of the experiment. This would be in line with the notion that high FO intake might impair the host's resistance to inflammatory stress, or to suppress the capability to overcome the inflammatory stimulus. We observed that plasma TBXB~2~ levels, a compound related to TBXA~2~ which is involved in vasoconstriction (Sellers and Stallone [@CR48]), was decreased in the 3 % FO group compared to the 1 % FO group, but also by LPS. The combination 3 % FO and LPS treatment might have caused a decrease in TBXA~2~ levels below its physiological range, potentially increasing the risk of inducing excessive vasodilatation and shock. Alternatively, pre-treatment of rats with a CB1 blocker was effective in reducing hypotension after LPS administration (Varga et al. [@CR54]), suggesting that increases in endocannabinoids after LPS might also contribute to the shock observed for the 3 % FO + LPS group. Future work should point out which (combination of) metabolites account for the impaired resistance in the 3 % FO + LPS group. Furthermore, future work should clarify which intake levels of n-3 fatty acids are beneficial to reduce symptoms of inflammatory diseases and where the inhibition of inflammation starts to interfere with an efficient response to an inflammatory stimulus.

In conclusion, dietary FO caused marked changes in the n-3 to n-6 balance of the endocannabinoid and oxylipin metabolomes, with specific effects depending on inflammatory status. The effects on metabolites are in line with the anti-inflammatory effects associated with n-3 fatty acid intake.
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